Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALBIREO PHARMA, INC.

(ALBO)
  Report
Delayed Nasdaq  -  04:00 2022-12-06 pm EST
22.05 USD   -2.82%
12/06Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
12/06Albireo Pharma, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
12/06Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ALBIREO PHARMA, INC.
12/06Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
12/06Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., t..
AQ
12/06Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson ..
CI
11/30Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
GL
11/30Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
AQ
11/09Albireo to Participate in Jefferies London Healthcare Conference
AQ
11/09Wedbush Trims Albireo Pharma's Price Target to $53 From $54 on Increased Share Count, K..
MT
11/08Albireo Pharma Swings to Q3 Loss, Revenue Rises; Shares Drop
MT
11/08Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End..
CI
11/08Transcript : Albireo Pharma, Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Earnings Flash (ALBO) ALBIREO PHARMA Reports Q3 Revenue $9.8M, vs. Street Est of $9.54M
MT
11/08Albireo Reports Q3 2022 Financial Results and Business Update
AQ
11/08Albireo Pharma, Inc. - Bylvay Data Presented at AASLD The Liver Meeting 2022, Demonstra..
AQ
11/07Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Nat..
AQ
11/07Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liv..
CI
More most relevant news
All news about ALBIREO PHARMA, INC.
12/06Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
12/06Albireo Pharma, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure..
AQ
12/06Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., t..
AQ
12/06Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson ..
CI
11/30Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
GL
11/30Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
AQ
11/09Albireo to Participate in Jefferies London Healthcare Conference
AQ
11/09Wedbush Trims Albireo Pharma's Price Target to $53 From $54 on Increased Share Count, K..
MT
11/08Albireo Pharma Swings to Q3 Loss, Revenue Rises; Shares Drop
MT
11/08ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
News in other languages on ALBIREO PHARMA, INC.
12/06Albireo Pharma, Inc. nomme Paul Streck au poste de directeur médical et Craig Hopkinson..
11/30Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (..
11/30Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (..
11/08Albireo Pharma enregistre une perte au troisième trimestre, mais le chiffre d'affaires ..
11/08Albireo Pharma, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois..
11/07Albireo Pharma, Inc. présente de nouvelles données à l'Association américaine pour l'ét..
11/02Albireo Pharma achève le recrutement de patients dans un essai de phase 3 pour le trait..
11/02Albireo Pharma, Inc. Termine le recrutement de l'étude BOLD de phase 3 de Bylvay(R) dan..
11/01Albireo Pharma, Inc. présentera des données de dernière minute sur Bylvay (odevixibat) ..
10/19Albireo meldet positive Topline-Daten aus Phase-3-Studie zu Bylvay® (Odevixibat) beim A..
More news
Analyst Recommendations on ALBIREO PHARMA, INC.
11/09Wedbush Trims Albireo Pharma's Price Target to $53 From $54 on Increased Share Count, K..
MT
10/12HC Wainwright Adjusts Albireo Pharma Price Target to $68 From $54, Maintains Buy Rating
MT
10/12Baird Raises Albireo Pharma's Price Target to $55 From $43, Maintains Outperform Rating
MT
10/11Wedbush Adjusts Albireo Pharma Price Target to $54 From $52, Maintains Outperform Ratin..
MT
09/23Baird Adjusts Albireo Pharma's Price Target to $43 from $40, Maintains Outperform Ratin..
MT
More recommendations
Press releases
12/06Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
12/06Albireo Pharma, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure..
AQ
12/06Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., t..
AQ
11/30Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
GL
11/30Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &..
AQ
More press releases
Upcoming event on ALBIREO PHARMA, INC.